Tools

Search

Explore

Videos Channels Figures

Atmrix

About

Tools

Search

Explore

Videos Channels Figures

Atmrix

About

EI

Elizabeth Iorns

10/03/18

@ Y Combinator

Access to capital and FDA's development strategies for rare diseases have enabled small biotech companies to bring products to market without being acquired.

Video

YC

A Conversation with Elizabeth Iorns - Advice for Biotech Founders

@ Y Combinator

A Conversation with Elizabeth Iorns - Advice for Biotech Founders

10/03/18

Related Takeaways

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

Successful biotech funds often incubate ideas internally before spinning them out as independent companies, which has proven effective in the industry.

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

There's a significant gap in funding for early-stage biotech discoveries, leading many companies to apply to Y Combinator when they have initial data suggesting a promising approach to curing diseases.

EI

Elizabeth Iorns

10/03/18

@ Y Combinator

Recent approvals of gene therapies and cell-based therapies have opened new avenues for biotech companies to create marketable products.

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

The focus for biotech companies is on de-risking their technology by obtaining experimental data and developing a viable therapeutic intervention, which is crucial before entering clinical trials.

EI

Elizabeth Iorns

10/03/18

@ Y Combinator

The biotech industry is experiencing a surge in startups due to unprecedented access to capital and advancements in therapeutic modalities.

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

Biotech fundraising is increasingly resembling traditional paths seen in software, with many funds showing interest in innovative science companies.

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

There is a growing interest from early-stage technology investors in funding biotech companies, with many successfully raising significant seed funding.

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

Biotech companies often use their time in Y Combinator to conduct critical path experiments and work with external companies for proof of concept studies, which can advance their regulatory filing status.

RS

Reshma Shetty

06/01/16

@ Y Combinator

In 2008, during the financial crisis, many biotech companies were going out of business, which made it a challenging time to raise money.